EGFR and colorectal carcinoma: Through a high-throughput synthetic lethal screen, biochemical assays, and treatment experiments using KRASG12D-mutant CRC cells, organoids, and xenograft models, we revealed that feedback activation of epidermal growth factor receptor (EGFR)-mediated wild-type RAS signaling contributed to the decreased effectiveness of KRASG12D inhibitor therapy in CRC.